NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada, a bio-pharmaceutical company (www.kamada.com) engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today of successful interim results in a Phase II deposition study with its Aerosolized AAT product delivered by PARI’s optimized eFlow® electronic nebulizer to treat Alpha-1 Deficiency and other respiratory diseases.
